Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Rituxan (Genentech Inc): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Rituxan (Genentech Inc) - General Information

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituxan (Genentech Inc) is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

 

Pharmacology of Rituxan (Genentech Inc)

Rituxan binds to the CD20 antigen, which is predominantly expressed on mature B cells and on > 90% of B-cell
non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.

 

Rituxan (Genentech Inc) for patients

 

Rituxan (Genentech Inc) Interactions

Drug/Laboratory Interactions: There have been no formal drug interaction studies performed with RITUXAN. However, renal toxicity was seen with this drug in combination with cisplatin in clinical trials.

 

Rituxan (Genentech Inc) Contraindications

RITUXAN is contraindicated in patients with known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of this product

 

Additional information about Rituxan (Genentech Inc)

Rituxan (Genentech Inc) Indication: For treatment of B-cell non-Hodgkins lymphoma (CD20 positive) Mechanism Of Action: Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Rituximab Synonyms: AntiCD20; Ig gamma-1 chain C region Drug Category: Antineoplastic Agents Drug Type: Biotech; Approved Other Brand Names containing Rituximab: Rituxan (Genentech Inc); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production Half Life: 0.8 hours (mammalian reticulocytes, in vitro) Dosage Forms of Rituxan (Genentech Inc): Solution Intravenous Chemical IUPAC Name: Chimeric murine/human monoclonal anti-CD20 antibody Chemical Formula: C6416H9874N1688O1987S44 Rituximab on Wikipedia: https://en.wikipedia.org/wiki/Rituximab Organisms Affected: Humans and other mammals